NIH, 10 drug makers in $230m+ pact to attack Alzheimer's, other diseases
This article was originally published in Scrip
Executive Summary
The National Institutes of Health (NIH) is setting off on a new $230m five-year venture with 10 biopharmaceutical companies and several nonprofits aimed at using biomarkers to accelerate the development of new diagnostics and targeted therapies, with the hopes of reducing the costs and increasing the chances those products will succeed.